Sumitomo Dainippon Pharma Acquires Patent License from DNAVEC On Clinical-grade iPS Cell Production Technology
Sumitomo Dainippon Pharma and SanBio Conclude Joint Development and License Agreement for North America With Respect to SB623, a Therapy for Stroke
"Corporate profile" An English version and a Japanese version are updated.
Sumitomo Dainippon Pharma Announces Transfer of Certain Fixed Assets
Latuda (lurasidone), a New Atypical Antipsychotic Agent for Adults with Schizophrenia, Now Available in the UK, Offers a Combination of Efficacy with Tolerability
Posted Conference Call for First Quarter Financial Results for FY2014 [Webcast]
A Message from the President
Board of Directors and Executive Officers